| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 7, 2005
Accepted on February 23, 2006
Diabetes Branch, Mouse Metabolism Core Laboratory, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland. 20892. Division of Endocrinology. University of North Carolina, Chapel Hill, North Carolina 27599
* To whom correspondence should be addressed. E-mail: derek{at}helix.nih.gov.
Insulin-like growth factor 1 (IGF-1) and insulin are structurally related polypeptides that mediate a similar pattern of biological effects via receptors that display considerably homology. Administration of recombinant human IGF-1 (rhIGF-1) has been proven to improve glucose control and liver and muscle insulin sensitivity in patients with type 2 diabetes mellitus (DM). The effect of rhIGF-1 treatment was evaluated in a mouse model of type 2 DM (MKR mouse) which expresses a dominant negative form of the human IGF-1R under the control of the muscle creatine kinase promoter specifically in skeletal muscle. MKR mice have impaired IGF-1 and insulin signaling in skeletal muscle leading to severe insulin resistance in muscle, liver and fat, developing type 2 DM at five weeks of age. Six week old MKR mice were treated either saline or rhIGF-1 for 3 weeks. Blood glucose levels were decreased in response to rhIGF-1 treatment in MKR mice. rhIGF-1 treatment also increased body weight in MKR with concomitant changes in body composition such as a decrease in fat mass and an increase in lean body mass. Insulin, fatty acid and triglyceride levels were not affected by rhIGF-1, nor were insulin (ITT) or glucose (GTT) tolerance in MKR mice. Hyperinsulinemic-euglycemic clamp analysis demonstrated no improvement in overall insulin sensitivity. Pyruvate and glutamine tolerance tests proved that there was a decrease in the rate of glucose appearance in MKR mice treated with rhIGF-1 suggesting a reduction in the gluconeogenic capacity of liver, kidney and small intestine. Taken together these results demonstrate that the improvement of the hyperglycemia was achieved by inhibition of gluconeogenesis rather than an improvement in insulin sensitivity. Also, these results suggest that a functional IGF-1R in skeletal muscle is required for IGF-1 to improve insulin sensitivity in this mouse model of type 2 DM.
This article has been cited by other articles:
 |
|
 |
|
  M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Robertson, Y. Lu, K. De Jesus, B. Li, Q. Su, P. K. Lund, and J.-L. Liu A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E928 - E938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ryan and P. E. Goss The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer Oncologist, January 1, 2008; 13(1): 16 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Haluska, H. M. Shaw, G. N. Batzel, D. Yin, J. R. Molina, L. R. Molife, T. A. Yap, M. L. Roberts, A. Sharma, A. Gualberto, et al. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5834 - 5840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Clemmons, M. Sleevi, G. Allan, and A. Sommer Effects of Combined Recombinant Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein-3 in Type 2 Diabetic Patients on Glycemic Control and Distribution of IGF-I and IGF-II among Serum Binding Protein Complexes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2652 - 2658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Murphy Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology, June 1, 2006; 147(6): 2616 - 2618. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
